Head-to-head · free
Genmab vs UnitedHealth Group
GMAB vs UNH — return on capital, cash generation, margins and balance sheet side by side.
GMAB
4 / 5
measures where GMAB leads
UNH
1 / 5
measures where UNH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | GMAB | UNH · FY2025 |
|---|---|---|
| Revenue | — | $447.6B |
| Net income | — | $12.1B |
| Revenue growth (yearly, multi-year) | — | 11.7% |
| Free cash flow | — | $16.1B |
| Free cash flow margin | — | 3.6% |
| Net cash / (debt) | — | (54.0B) |
| ROIC | 10.1% | 9.2% |
| Return on equity | 17.5% | 12.9% |
| Gross margin | 93.6% | 18.5% |
| Operating margin | 33.6% | 4.2% |
| Net debt / EBITDA | 3.13x | 2.32x |
Figures are as reported by each company; latest fiscal year shown.
Where UnitedHealth Group's cash went (FY2025)
- Capital spending
- $3.6B
- Buybacks
- $5.5B
- Dividends
- $7.9B
- Acquisitions
- $4.5B
- Net debt issued / (repaid)
- $726.0M
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free